hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06326333 id: E.Kurul-E2-24-6176 briefTitle: Combination of Parasternal and Serratus Anterior Plane Block in Coronary Artery Bypass Graft Surgery overallStatus: COMPLETED date: 2024-02-07 date: 2024-03-27 date: 2024-04-18 date: 2024-03-22 date: 2024-04-22 name: Ankara City Hospital Bilkent class: OTHER briefSummary: Postoperative analgesia is a critical risk factor for the development of pulmonary and cardiovascular complications in coronary artery bypass graft (CABG) surgery. If patients with high pain levels cannot breathe effectively, it may lead to atelectasis, cardiac ischemia, and arrhythmias. This prolongs the time it takes for patients to be discharged and increases the frequency of postoperative pulmonary complications and postoperative morbidity.
In addition to intravenous medications, various neuraxial and peripheral nerve blocks can be used in cardiac surgery. In recent years, neuraxial anesthesia has been avoided due to the use of intraoperative high-dose heparin. As an alternative, peripheral nerve blocks have recently gained popularity. Parasternal block (PSB) and serratus anterior plane block (SAPB) are very superficial and easy to reach. Recently, in the literature, the number of cases performed with these blocks under ultrasound guidance and the number of randomized controlled prospective studies have increased.
With this study, it was aimed to observe the analgesic effects on both the sternum and the drain site by applying PSB and SAPB applications simultaneously in the postoperative analgesia of CABG patients. conditions: Parasternal Block conditions: Serratus Anterior Plane Block conditions: Acute Pain conditions: Postoperative Analgesia conditions: Cardiac Surgery studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ACTUAL name: Combined parasternal block and serratus anterior plane block measure: Pain Scores measure: Pain Scores measure: Pain Scores measure: Pain Scores measure: Pain Scores measure: Remifentanyl Consumption sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ankara City Hospital city: Çankaya state: Ankara zip: 06290 country: Turkey lat: 39.9179 lon: 32.86268 hasResults: False
nctId: NCT06326320 id: E.Kurul-E2-24-6175 briefTitle: Combined SAPB in MICS overallStatus: RECRUITING date: 2024-02-07 date: 2024-05-07 date: 2024-05-17 date: 2024-03-22 date: 2024-03-25 name: Ankara City Hospital Bilkent class: OTHER briefSummary: Minimally invasive cardiac surgery (MICS) has begun to be performed frequently in recent years. Compared to sternotomy, MISC reduces the risk of mediastinitis, leaves a more aesthetic scar, facilitates postoperative rehabilitation, and shortens the hospital stay. MICS requires a thoracic incision in the right 4th or 5th intercostal space. This incision causes intense and long-lasting pain in the postoperative period. Pain is exacerbated by breathing movements, coughing, and respiratory physiotherapy.
In addition to intravenous medications, various neuraxial and peripheral nerve blocks can be used in cardiac surgery. In recent years, thoracic epidural analgesia has been avoided due to the use of intraoperative high-dose heparin. As an alternative, peripheral nerve blocks have recently gained popularity. SAPB is one of them. SAPB can be applied in three ways. While deep SAPB (DSAPB) is applied under the serratus anterior muscle, superficial SAPB (SSAPB) is applied above the serratus anterior muscle. Combined SAPB (CSAPB) is applied both below and above the serratus anterior muscle. These blocks can be performed with a single injection anywhere between the second and seventh ribs on the lateral chest wall.
In this study, the analgesic effects of ultrasound-guided CSAPB application in patients undergoing MICS will be evaluated. conditions: Serratus Anterior Plane Block conditions: Acute Pain conditions: Postoperative Analgesia conditions: Minimal Invasive Cardiac Surgery studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: Combined SAPB measure: Pain Scores measure: Pain Scores measure: Pain Scores measure: Pain Scores measure: Pain Scores measure: Remifentanyl Consumption sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ankara City Hospital status: RECRUITING city: Çankaya state: Ankara zip: 06290 country: Turkey name: Emine N Zengin, MD role: CONTACT phone: +905063370548 email: nilbavullu@gmail.com lat: 39.9179 lon: 32.86268 hasResults: False
nctId: NCT06326307 id: 247-05-21 briefTitle: Effectiveness of Puppet Modeling Technique on Children Undergoing Stressful Dental Procedures overallStatus: COMPLETED date: 2023-01-01 date: 2023-12-01 date: 2023-12-01 date: 2024-03-22 date: 2024-03-22 name: King Abdulaziz University class: OTHER briefSummary: The goal of this RCT is to compare puppet modeling technique vs tell show and do on children undergoing stressful dental procedures'
* Group II : Children who received the tell-show-do behavior guidance during their first visit and puppet behavioral guidance in their second visit, 2 weeks later.(TSD-P) conditions: Behavioral Guidance in Pediatric Dentistry studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: * Group I : Children who received puppet behavior guidance during their first visit and tell-show-do guidance in their second visit, 2 weeks later. (P-TSD)
* Group II: Children who received the tell-show-do behavior guidance during their first visit and puppet behavioral guidance in their second visit, 2 weeks later.(TSD-P) primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Two evaluators, who are blinded to the experimented techniques, watched recorded videos of both groups separately and gave their behavior assessment. whoMasked: OUTCOMES_ASSESSOR count: 41 type: ACTUAL name: Tell Show and Do Guidance name: Puppet Guidance measure: Heart rate measure: Facial Image Scale measure: Vehnam Anxiety Rating Scale measure: Frankl behavior rating scale measure: FLACC Pain scale measure: Venham Scale of Dental behavior sex: ALL minimumAge: 3 Years maximumAge: 8 Years stdAges: CHILD facility: King Abulaziz university dental hospital city: Jeddah state: Makkah zip: 21589 country: Saudi Arabia lat: 21.54238 lon: 39.19797 hasResults: False
nctId: NCT06326294 id: 727/CNBS/23 briefTitle: Assessment of the Effectiveness of TA Versus LEEP for Cervical Cancer Risk Reduction in WLHIV in Mozambique overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2027-09 date: 2027-12 date: 2024-03-22 date: 2024-03-22 name: Instituto Nacional de Saúde, Mozambique class: OTHER_GOV name: M.D. Anderson Cancer Center briefSummary: Given that WLWH are more likely to develop persistent HPV infection and CC, effective screening and the management and treatment of pre-cancerous cervical abnormalities is critical to decrease the global burden of cervical cancer. The vast majority of WLWH live in SSA, where resources are more constrained. Therefore, simple, affordable, and effective tools are needed for the prevention of cervical cancer in SSA. In this setting, the best method for treatment of screen-positive WLWH has not been determined. The proposed study will compare the effectiveness of TA vs. LEEP, for treating precursor lesions (CIN 2/3) and HPV infection in WLWH, identify the determinants of treatment failure, and develop a strategy to predict patients in whom treatment is likely to fail so that alternative treatments can be provided. Moreover, local evidence of the optimal method of treatments is necessary to inform health policy and promote adherence. conditions: HIV Infections conditions: HPV Infection conditions: CIN 2/3 studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: To compare TA, an ablative cervical treatment modality, and LEEP, an excisional cervical treatment modality, in screen-positive WLWH patients, for eradication of hrHPV and effectiveness of treating biopsy-confirmed CIN 2/3. primaryPurpose: TREATMENT masking: NONE count: 4844 type: ESTIMATED name: Thermal ablation name: LOOP ELECTROSURGICAL EXCISION PROCEDURE measure: Comparison of treatment success rates for biopsy-confirmed CIN 2/3: Thermoablation (TA) vs. Loop Electrosurgical Excision Procedure (LEEP) sex: FEMALE minimumAge: 25 Years maximumAge: 49 Years stdAges: ADULT facility: INSMozambique city: Maputo country: Mozambique lat: -25.96553 lon: 32.58322 hasResults: False
nctId: NCT06326281 id: ACHBILKENT-ANEST-BK-01 briefTitle: Postoperative Pain Management in Laparoscopic Cholecystectomies overallStatus: COMPLETED date: 2023-07-01 date: 2024-02-22 date: 2024-02-28 date: 2024-03-22 date: 2024-03-22 name: Ankara City Hospital Bilkent class: OTHER briefSummary: This study is to demonstrate the effectiveness of external oblique intercostal plane block, a new block method, in the treatment of postoperative pain occurring after laparoscopic cholecystectomy operations, which are frequently and widely performed today.
It aims to add new applications to multimodal analgesia methods, which provide the greatest contribution to the early recovery process after surgery, and to contribute to the early recovery process by increasing patient satisfaction. conditions: Cholecystitis/Cholelithiasis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Evaluation of postoperative pain in 4 groups in laparoscopic cholecystectomy with control group primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Patients were not told which method would be used The person evaluating the patients did not know which method was applied to which patient. whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 100 type: ACTUAL name: external oblique intercostal plane block group name: oblique subcostal TAP block group name: Local anesthetic infiltration group name: control group measure: Visual Analogue Scale Score sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ankara Bılkent City Hospital city: Ankara zip: 06100 country: Turkey lat: 39.91987 lon: 32.85427 hasResults: False
nctId: NCT06326268 id: 2023-019 id: 2023-A02133-42 type: OTHER domain: ID-RCB Number briefTitle: Interest of Light Therapy in Hematology - The PHOTO-TREAT Study acronym: PHOTO-TREAT overallStatus: RECRUITING date: 2024-04-17 date: 2025-09-17 date: 2025-09-17 date: 2024-03-22 date: 2024-04-22 name: Institut de cancérologie Strasbourg Europe class: OTHER briefSummary: Chemo-induced mucositis is a common complication in patients treated for hematologic malignancies. They can manifest itself as a simple local irritation with erythema and inflammation but can also progress to erosions and ulcerations of the entire oral mucosa and are also responsible for an increased risk of infection in these immunocompromised patients.
The only therapies currently offered are local care and intravenous analgesics. Studies in pediatric hematology show the effectiveness of prevention and low-dose laser treatment in chemo-induced mucositis, both in terms of reducing the number of mucositis developed but also in terms of reducing the grade of mucositis. This currently results in a recommendation for the use of photobiomodulation by international bodies such as ESMO (European Society for Medical Oncology). conditions: Leukemia, Myeloid, Acute conditions: Lymphoma studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 30 type: ESTIMATED name: Phototherapy system CareMin650TM measure: Evaluate the impact of Photobiomodulation (PBM) therapy in the management of chemo-induced mucositis in terms of prevalence of mucositis measure: Evaluate the impact of PBM in the management of chemo-induced mucositis in terms of reduction in analgesic consumption. measure: Evaluate the impact of PBM in terms of infection by bacterial translocation risk reduction. measure: Evaluate the impact of PBM in terms of reduction of the use of artificial feeding. measure: Evaluate the impact of PBM in terms of reduction of the length of hospital stay. measure: Evaluate the impact of PBM in terms of reduction of the number of transfusions. measure: Evaluate the impact of PBM in terms of pain reduction measure: Evaluate the impact of PBM on patient's satisfaction regarding pain management during hospital stay sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Institut de cancérologie Strasbourg Europe status: RECRUITING city: Strasbourg zip: 67033 country: France role: CONTACT phone: (0)3 68 33 95 23 phoneExt: +33 email: promotion-rc@icans.eu name: Anne ZILLIOX, MD role: PRINCIPAL_INVESTIGATOR lat: 48.58392 lon: 7.74553 hasResults: False
nctId: NCT06326255 id: LYASD briefTitle: Feasibility and Acceptability of Laughter Yoga in Children With Autism Spectrum Disorder and Their Parents overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2024-10-01 date: 2025-12-31 date: 2024-03-22 date: 2024-03-22 name: The Hong Kong Polytechnic University class: OTHER briefSummary: This is a pilot randomised controlled trial to explore the acceptability and feasibility of laughter yoga about anxiety and depression reduction in children with ASD and parenting stress reduction for their parents. Hypotheses of this study include:
3. Participants in the experimental group will have significantly more reduction in depression, anxiety and parental stress than those in the wait-list-control group. conditions: Autism Spectrum Disorder conditions: Parenting Stress conditions: Depression conditions: Anxiety studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 66 type: ESTIMATED name: laughter yoga measure: Response rate measure: Attrition rate measure: Attendance rate measure: Perception on laughter yoga measure: Difficulties in laughter yoga measure: Safety issues measure: Depression measure: Anxiety measure: Parenting Stress measure: Child-parent Relationships sex: ALL minimumAge: 8 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: The Hong Kong Polytechnic University city: Hong Kong country: Hong Kong lat: 22.27832 lon: 114.17469 hasResults: False
nctId: NCT06326242 id: IEO 1648 briefTitle: What Unmet Need for the Patients?A Focus on the Social Determinants of Health in Phase 1 Clinical Trials overallStatus: RECRUITING date: 2023-03-27 date: 2024-12-31 date: 2024-12-31 date: 2024-03-22 date: 2024-03-22 name: European Institute of Oncology class: OTHER briefSummary: An observational prospective study of patients enrolled and treated with experimental drugs in Phase I studies. conditions: Solid Tumor studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: Solid Tumor measure: The geographical accessibility of patients attending the Phase 1 facility of the European Institute of Oncology (IEO). measure: The characterization of enrolled patients involves assessing their participation in clinical trials measure: The characterization of enrolled patients based on therapeutic compliance. measure: The protocol prescriptions in relation to socioeconomic and geographical determinants. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: European Institute of oncology status: RECRUITING city: Milano zip: 20141 country: Italy name: Teresa Profeta role: CONTACT phone: +390294372561 lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06326229 id: CEIm 3096 briefTitle: Clinical Validation of Musculoskeletal ICF Core Set in Primary Care Physiotherapy overallStatus: NOT_YET_RECRUITING date: 2024-05-06 date: 2025-01-31 date: 2025-09-26 date: 2024-03-22 date: 2024-04-05 name: University of Valladolid class: OTHER name: Castilla-León Health Service briefSummary: The aim of this observational study is to validate the content of a tailored ICF core set for the management of musculoskeletal conditions in primary care physiotherapy services.
Participants will evaluate the relevance of each ICF entity included in the ICF core set according to their musculoskeletal condition. conditions: Musculoskeletal Diseases studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 385 type: ESTIMATED name: ICF entities assessment measure: ICF core set for post-acute musculoskeletal conditions (adapted version for primary care physiotherapy services) measure: Sociodemographic data of the sample sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ólvega Primary Care Physiotherapy service city: Ólvega state: Soria zip: 42110 country: Spain name: Héctor Hernández Lázaro, PhD role: CONTACT phone: +34976645480 phoneExt: 38229 email: hhernandezl@saludcastillayleon.es lat: 41.77901 lon: -1.98391 hasResults: False
nctId: NCT06326216 id: 19-011292 id: NCI-2023-05221 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: 19-011292 type: OTHER domain: Mayo Clinic Institutional Review Board briefTitle: Determination of Baseline Levels for Prostate Cancer-Derived Extracellular Vesicles Following Local Treatment of Prostate Cancer overallStatus: RECRUITING date: 2020-06-10 date: 2025-07-01 date: 2025-07-01 date: 2024-03-22 date: 2024-03-22 name: Mayo Clinic class: OTHER briefSummary: This study is being done to determine whether levels of prostate cancer derived extracellular vesicles from blood and urine specimens correlate with response to primary local treatment (surgery) in prostate cancer. conditions: Prostate Carcinoma studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: Non-Interventional Study measure: Levels of prostate cancer-derived extracellular vesicles (EVs) - radical prostatectomy measure: Levels of prostate cancer-derived extracellular vesicles (EVs) - negative controls measure: Correlation between prostate specific antigen (PSA) levels and prostate cancer-derived EVs measure: Prostate cancer-derived EV levels sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic in Rochester status: RECRUITING city: Rochester state: Minnesota zip: 55905 country: United States name: Clinical Trials Referral Office role: CONTACT phone: 855-776-0015 email: mayocliniccancerstudies@mayo.edu name: Eugene D. Kwon, M.D. role: PRINCIPAL_INVESTIGATOR lat: 44.02163 lon: -92.4699 hasResults: False
nctId: NCT06326203 id: UPECLIN-MB-8 briefTitle: Cell Therapy for Lower Limb Ulcers in Patients With Critical Limb Ischemia overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2027-07-01 date: 2027-12-31 date: 2024-03-22 date: 2024-04-10 name: UPECLIN HC FM Botucatu Unesp class: OTHER name: Conselho Nacional de Desenvolvimento Científico e Tecnológico briefSummary: Peripheral arterial disease (PAD) can progress to critical limb ischemia (CLI) of the affected lower limb, characterized by pain at rest, ulcerations or gangrene, with a high risk of amputation. In this phase, the best treatment is arterial limb revascularization, but this is not always possible or even effective for promoting pain relief, healing of ulcers or preventing amputations, in addition to the high socioeconomic cost caused by the disease. Recent advances in cell therapy represent a promising supporting alternative for the treatment of PAD in cases where conventional alternatives have run out. Objective: To evaluate the safety and efficacy of cell therapy with expanded autologous mesenchymal stem cells in the treatment of patients with PAD with CLI and chronic arterial ulcers. Methods: An open randomized clinical study will be performed with 2 groups of 20 patients with CLI: in group 1, a fragment of abdominal fat tissue (10g) will be collected to obtain mesenchymal stem cells, which will be expanded and applied using subcutaneous perilesional injection in the affected lower limb, in addition to the application in the form of a personalized curative biological on the wounds. Group 2 will receive conventional treatment with a Hydrogel dressing with essential fatty acids. Periodic clinical evaluations, complementary exams and photographic record will be carried out. The main outcome of effectiveness will be partial or total wound healing. Safety outcomes will be monitored for infections, gangrene, amputations and deaths. Participants will be monitored for 120 days. Major amputation cases will not be included. An independent external evaluator and blind to the groups will evaluate the results. It is an innovative procedure with high impact and financial return for SUS, in view of the high prevalence of the disease and the high socioeconomic impact of the disease when it progresses to limb amputation. conditions: Peripheral Arterial Disease conditions: Leg Ulcer studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: CELULAS TRONCO name: CONVENTIONAL DRESSING measure: Major Amputation measure: Ulcer Healing sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06326190 id: EORTC-2334-BTG briefTitle: 177Lu-DOTATATE for Recurrent Meningioma acronym: LUMEN-1 overallStatus: NOT_YET_RECRUITING date: 2024-11-06 date: 2027-04-14 date: 2028-12-22 date: 2024-03-22 date: 2024-03-22 name: European Organisation for Research and Treatment of Cancer - EORTC class: NETWORK name: Novartis briefSummary: Novel treatments are urgently needed for meningiomas progressing after local therapies (surgery, radiotherapy). So far, no effective systemic therapies are known in this situation. The LUMEN-1 trial will investigate in a prospective randomized trial the efficacy of the precision medicine "theranostic" concept of combining diagnostic patient selection using PET-based molecular imaging and target-specific therapeutic intervention using a systemically administered radioligand.
The rationale for the LUMEN-1 trial is based on the following: (a) high somatostatin receptor (SSTR) expression in meningiomas, (b) wide-spread availability of clinically established SSTR-PET imaging, (c) proven efficacy of SSTR-targeting radioligand therapy using \[177Lu\]Lu-DOTATATE in another tumor type (neuroendocrine tumors), and (d) promising experiences with \[177Lu\]Lu-DOTATATE therapy in compassionate use applications and retrospective case series and interim results from one ongoing uncontrolled prospective trial in meningiomas. LUMEN-1 is the first randomized clinical trial to investigate \[177Lu\]Lu-DOTATATE therapy in refractory meningioma and may open new avenues for treatment and research in this area. conditions: Recurrent Meningioma studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 135 type: ESTIMATED name: Local standard of Care name: 177Lu-DOTATATE measure: Progression Free Survival (PFS) measure: Overall Survival (OS) measure: Radiological response rate measure: Radiological response rate measure: The magnitude of change in Health-related quality of life (HRQoL) measure: The magnitude of change in Health-related quality of life (HRQoL) measure: The magnitude of change in Health-related quality of life (HRQoL) measure: Neurological function (NANO scale) measure: Toxicity According to CTCAE Version 5.0 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False